ResearcherKeimyung UniversityActive in the last 2 years

Seongjun Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2622-8324; OpenAlex author ID A5100777272. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells. Co-author DOI 10.4014/jmb.2412.12032 ↗
ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. Co-author DOI 10.1007/s12272-021-01359-x ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Won‐Jun Jang · 2 shared papers, 2021–2025 · strength 0.49
- Paper Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells. DOI 10.4014/jmb.2412.12032 ↗
- Paper ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. DOI 10.1007/s12272-021-01359-x ↗
Chul‐Ho Jeong · 2 shared papers, 2021–2025 · strength 0.49
- Paper Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells. DOI 10.4014/jmb.2412.12032 ↗
- Paper ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. DOI 10.1007/s12272-021-01359-x ↗
Dong Joon Kim · 1 shared paper, 2025 · strength 0.33
- Paper Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells. DOI 10.4014/jmb.2412.12032 ↗
Dong-Hwan Kim · 1 shared paper, 2025 · strength 0.33
- Paper Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells. DOI 10.4014/jmb.2412.12032 ↗
Sang Hoon Joo · 1 shared paper, 2021 · strength 0.16
- Paper ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. DOI 10.1007/s12272-021-01359-x ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.